Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A; Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

Int J Clin Oncol. 2018 Apr 26. doi: 10.1007/s10147-018-1281-8. [Epub ahead of print]

PMID:
29700636
2.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Mar 5. doi: 10.1093/jnci/djy022. [Epub ahead of print]

PMID:
29514301
3.

EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.

Li Z, Takenobu H, Setyawati AN, Akita N, Haruta M, Satoh S, Shinno Y, Chikaraishi K, Mukae K, Akter J, Sugino RP, Nakazawa A, Nakagawara A, Aburatani H, Ohira M, Kamijo T.

Oncogene. 2018 May;37(20):2714-2727. doi: 10.1038/s41388-018-0133-3. Epub 2018 Mar 6.

4.

Neuroblastoma.

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M.

Jpn J Clin Oncol. 2018 Mar 1;48(3):214-241. doi: 10.1093/jjco/hyx176. Review.

PMID:
29378002
5.

Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J.

Oncotarget. 2017 Nov 18;8(64):107513-107529. doi: 10.18632/oncotarget.22495. eCollection 2017 Dec 8.

6.

Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx062.

PMID:
29059438
7.

Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A.

Oncotarget. 2017 May 23;8(34):56684-56697. doi: 10.18632/oncotarget.18079. eCollection 2017 Aug 22.

8.

Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, States LJ, Walsh MF, Diller LR, Brodeur GM.

Clin Cancer Res. 2017 Jul 1;23(13):e98-e106. doi: 10.1158/1078-0432.CCR-17-0652. Review.

9.

Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk.

Villani A, Greer MC, Kalish JM, Nakagawara A, Nathanson KL, Pajtler KW, Pfister SM, Walsh MF, Wasserman JD, Zelley K, Kratz CP.

Clin Cancer Res. 2017 Jun 15;23(12):e83-e90. doi: 10.1158/1078-0432.CCR-17-0631. Review.

10.

Neuroblastoma.

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA.

Nat Rev Dis Primers. 2016 Nov 10;2:16078. doi: 10.1038/nrdp.2016.78. Review.

PMID:
27830764
11.

Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.

Ho WL, Hsu WM, Huang MC, Kadomatsu K, Nakagawara A.

J Hematol Oncol. 2016 Sep 29;9(1):100. Review.

12.

Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.

Satoh S, Takatori A, Ogura A, Kohashi K, Souzaki R, Kinoshita Y, Taguchi T, Hossain MS, Ohira M, Nakamura Y, Nakagawara A.

Sci Rep. 2016 Sep 8;6:32682. doi: 10.1038/srep32682.

13.

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.

Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, London WB, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H.

PLoS One. 2016 Aug 11;11(8):e0161039. doi: 10.1371/journal.pone.0161039. eCollection 2016.

14.

Transcriptional regulation of BMCC1 mediated by E2F1 in neuroblastoma cells.

Islam MS, Tatsumi Y, Takano R, Yokochi T, Akter J, Ozaki T, Nakamura Y, Ohira M, Nakagawara A.

Biochem Biophys Res Commun. 2016 Sep 9;478(1):81-86. doi: 10.1016/j.bbrc.2016.07.089. Epub 2016 Jul 22.

PMID:
27453342
15.

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

Eur J Cancer. 2016 Sep;65:1-10. doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17.

PMID:
27434878
16.

Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.

Sheikh A, Takatori A, Hossain MS, Hasan MK, Tagawa M, Nagase H, Nakagawara A.

Cancer Sci. 2016 Sep;107(9):1223-32. doi: 10.1111/cas.13003. Epub 2016 Sep 2.

17.

Effects of novel small compounds targeting TrkB on neuronal cell survival and depression-like behavior.

Fukuda M, Takatori A, Nakamura Y, Suganami A, Hoshino T, Tamura Y, Nakagawara A.

Neurochem Int. 2016 Jul;97:42-8. doi: 10.1016/j.neuint.2016.04.017. Epub 2016 May 7.

PMID:
27166149
18.

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG.

Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28.

19.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL.

J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. Review.

20.

Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells.

Islam SM, Suenaga Y, Takatori A, Ueda Y, Kaneko Y, Kawana H, Itami M, Ohira M, Yokoi S, Nakagawara A.

Cancer Sci. 2015 Oct;106(10):1351-61. doi: 10.1111/cas.12746. Epub 2015 Aug 18.

21.

Oncogenic Lmo3 cooperates with Hen2 to induce hydrocephalus in mice.

Isogai E, Okumura K, Saito M, Yoshizawa Y, Itoh K, Tando S, Ohira M, Haraguchi S, Nakagawara A, Fushiki S, Nagase H, Wakabayashi Y.

Exp Anim. 2015;64(4):407-14. doi: 10.1538/expanim.15-0026. Epub 2015 Jul 6.

22.

NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells.

Shoji W, Suenaga Y, Kaneko Y, Islam SM, Alagu J, Yokoi S, Nio M, Nakagawara A.

Biochem Biophys Res Commun. 2015 Jun 5;461(3):501-6. doi: 10.1016/j.bbrc.2015.04.050. Epub 2015 Apr 17.

23.

Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.

Kaneko Y, Suenaga Y, Islam SM, Matsumoto D, Nakamura Y, Ohira M, Yokoi S, Nakagawara A.

Cancer Sci. 2015 Jul;106(7):840-7. doi: 10.1111/cas.12677. Epub 2015 May 19.

24.

Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma.

Nakazawa A, Haga C, Ohira M, Okita H, Kamijo T, Nakagawara A.

Cancer Sci. 2015 Jun;106(6):766-71. doi: 10.1111/cas.12665. Epub 2015 Apr 22.

25.

BMCC1, which is an interacting partner of BCL2, attenuates AKT activity, accompanied by apoptosis.

Tatsumi Y, Takano R, Islam MS, Yokochi T, Itami M, Nakamura Y, Nakagawara A.

Cell Death Dis. 2015 Jan 22;6:e1607. doi: 10.1038/cddis.2014.568.

26.

Intracellular fragment of NLRR3 (NLRR3-ICD) stimulates ATRA-dependent neuroblastoma differentiation.

Akter J, Takatori A, Islam MS, Nakazawa A, Ozaki T, Nagase H, Nakagawara A.

Biochem Biophys Res Commun. 2014 Oct 10;453(1):86-93. doi: 10.1016/j.bbrc.2014.09.065. Epub 2014 Sep 23.

PMID:
25256744
27.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

28.

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG.

J Clin Oncol. 2014 Oct 1;32(28):3169-76. doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25.

29.

Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.

Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR.

Pediatr Blood Cancer. 2014 Nov;61(11):1932-9. doi: 10.1002/pbc.25134. Epub 2014 Jul 7.

PMID:
25044743
30.

Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation.

Shimozato O, Waraya M, Nakashima K, Souda H, Takiguchi N, Yamamoto H, Takenobu H, Uehara H, Ikeda E, Matsushita S, Kubo N, Nakagawara A, Ozaki T, Kamijo T.

Oncogene. 2015 Apr 9;34(15):1949-60. doi: 10.1038/onc.2014.141. Epub 2014 Jun 2.

PMID:
24882578
31.

Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association.

Tomiyama A, Uekita T, Kamata R, Sasaki K, Takita J, Ohira M, Nakagawara A, Kitanaka C, Mori K, Yamaguchi H, Sakai R.

Cancer Res. 2014 Jul 15;74(14):3790-801. doi: 10.1158/0008-5472.CAN-14-0241. Epub 2014 May 15.

32.

RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.

Haruta M, Kamijo T, Nakagawara A, Kaneko Y.

Cancer Lett. 2014 Jun 28;348(1-2):167-76. doi: 10.1016/j.canlet.2014.03.022. Epub 2014 Mar 26.

PMID:
24680815
33.

Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

J Clin Oncol. 2014 Apr 20;32(12):1228-35. doi: 10.1200/JCO.2013.53.6342. Epub 2014 Mar 24.

34.

Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.

Yamaguchi Y, Takenobu H, Ohira M, Nakazawa A, Yoshida S, Akita N, Shimozato O, Iwama A, Nakagawara A, Kamijo T.

Eur J Cancer. 2014 May;50(8):1555-65. doi: 10.1016/j.ejca.2014.01.023. Epub 2014 Feb 19.

PMID:
24559687
35.

Identification of novel candidate compounds targeting TrkB to induce apoptosis in neuroblastoma.

Nakamura Y, Suganami A, Fukuda M, Hasan MK, Yokochi T, Takatori A, Satoh S, Hoshino T, Tamura Y, Nakagawara A.

Cancer Med. 2014 Feb;3(1):25-35. doi: 10.1002/cam4.175. Epub 2014 Jan 1.

36.

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.

Suenaga Y, Islam SM, Alagu J, Kaneko Y, Kato M, Tanaka Y, Kawana H, Hossain S, Matsumoto D, Yamamoto M, Shoji W, Itami M, Shibata T, Nakamura Y, Ohira M, Haraguchi S, Takatori A, Nakagawara A.

PLoS Genet. 2014 Jan;10(1):e1003996. doi: 10.1371/journal.pgen.1003996. Epub 2014 Jan 2.

37.

[A novel role of RUNX2 in the regulation of p53-dependent DNA damage response].

Ozaki T, Nakagawara A, Nagase H.

Seikagaku. 2013 Nov;85(11):1002-7. Review. Japanese. No abstract available.

PMID:
24364254
38.

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.

Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, Suenaga Y, Hossain S, Akter J, Ogura A, Nakamura Y, Kadomatsu K, Nakagawara A.

Sci Rep. 2013 Dec 20;3:3450. doi: 10.1038/srep03450.

39.

NFBD1/MDC1 is phosphorylated by PLK1 and controls G2/M transition through the regulation of a TOPOIIα-mediated decatenation checkpoint.

Ando K, Ozaki T, Hirota T, Nakagawara A.

PLoS One. 2013 Dec 11;8(12):e82744. doi: 10.1371/journal.pone.0082744. eCollection 2013.

40.

Two cases of neuroblastoma comprising two distinct clones.

Yamazaki F, Nakazawa A, Osumi T, Shimojima N, Tanaka T, Nakagawara A, Shimada H.

Pediatr Blood Cancer. 2014 Apr;61(4):760-2. doi: 10.1002/pbc.24779. Epub 2013 Sep 20.

PMID:
24108545
41.

RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response.

Ozaki T, Nakagawara A, Nagase H.

Int J Genomics. 2013;2013:271347. doi: 10.1155/2013/271347. Epub 2013 Sep 3. Review.

42.

High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.

Itakura M, Terashima Y, Shingyoji M, Yokoi S, Ohira M, Kageyama H, Matui Y, Yoshida Y, Ashinuma H, Moriya Y, Tamura H, Harigaya K, Matushima K, Iizasa T, Nakagawara A, Kimura H.

Br J Cancer. 2013 Sep 3;109(5):1100-8. doi: 10.1038/bjc.2013.440. Epub 2013 Aug 6.

43.

RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma.

Yu F, Gao W, Yokochi T, Suenaga Y, Ando K, Ohira M, Nakamura Y, Nakagawara A.

Oncogene. 2014 May 15;33(20):2601-9. doi: 10.1038/onc.2013.221. Epub 2013 Jul 15.

PMID:
23851507
44.

Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression.

Zhu Y, Li Y, Haraguchi S, Yu M, Ohira M, Ozaki T, Nakagawa A, Ushijima T, Isogai E, Koseki H, Nakamura Y, Kong C, Mehlen P, Arakawa H, Nakagawara A.

J Clin Invest. 2013 Jul;123(7):2935-47. doi: 10.1172/JCI65988. Epub 2013 Jun 17.

45.

Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas.

Asada K, Watanabe N, Nakamura Y, Ohira M, Westermann F, Schwab M, Nakagawara A, Ushijima T.

Jpn J Clin Oncol. 2013 Jun;43(6):641-5. doi: 10.1093/jjco/hyt058. Epub 2013 Apr 25.

PMID:
23619990
46.

Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.

Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A.

Cell Death Dis. 2013 Apr 25;4:e610. doi: 10.1038/cddis.2013.127.

47.

Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma.

Yamaki T, Suenaga Y, Iuchi T, Alagu J, Takatori A, Itami M, Araki A, Ohira M, Inoue M, Kageyama H, Yokoi S, Saeki N, Nakagawara A.

Sci Rep. 2013;3:1160. doi: 10.1038/srep01160. Epub 2013 Jan 29.

48.

Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.

Takagi D, Tatsumi Y, Yokochi T, Takatori A, Ohira M, Kamijo T, Kondo S, Fujii Y, Nakagawara A.

Cancer Sci. 2013 May;104(5):563-72. doi: 10.1111/cas.12115. Epub 2013 Mar 13.

49.

Apoptotic cell death in neuroblastoma.

Li Y, Nakagawara A.

Cells. 2013 Jun 20;2(2):432-59. doi: 10.3390/cells2020432.

50.

A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.

Sugimoto T, Gotoh T, Yagyu S, Kuroda H, Iehara T, Hosoi H, Ohta S, Ohira M, Nakagawara A.

Cancer Lett. 2013 Apr 30;331(1):115-21. doi: 10.1016/j.canlet.2012.12.011. Epub 2012 Dec 23.

PMID:
23268333

Supplemental Content

Loading ...
Support Center